drugset / Trial / NCT01192191

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

NCT01192191

Phase 3 Completed 187 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.

Timeline

Start
2010-08
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified 100 ug Inhaled
Subject Fluticasone Furoate Other / unclassified 200 ug Inhaled
Subject Vilanterol Other / unclassified 25 ug Inhaled